Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frequent Dosing Regimen of Lucentis for Persistent Diabetic Macular Edema
NCT02127684Phase 2Withdrawn
- Sponsor
- Raj K. Maturi MD
- Primary completion
- Aug 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in diabetic macular edema (DME), sponsored by Raj K. Maturi MD. Status: withdrawn.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02127684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127684.